The role of differences of metabolism in the formation of disorder of function of the liver and the kidney in tetrachloride carbon intoxication
Currently, there is a steady tendency for the growth of diseases of the hepatobiliary system, which is caused by a complex of endogenous and exogenous influences. Therefore, treatment of chronic hepatitis remains one of the important and complex problems in the general medicine clinic. The purpose of the study is to evaluate the role of some regulatory mechanisms in the formation of liver and kidney disorders in carbon tetrachloride intoxication. The experimental studies were performed on 54 white Wistar rats of the autohybrid breeding line, which were divided into control and experimental groups. Within 7 days, the experimental group of animals was subjected to carbon tetrachloride intoxication by administering 0.5 ml CCl₄ subcutaneously. Kidney function status was assessed by changes in diuretic diuresis, glomerular filtration function, percent tubular reabsorption, serum creatinine and urea content, chloride excretion and urine pH. Liver function was assessed by ALT and AST activity, bilirubin in the blood, serum creatinine and urea content, total serum protein. The status of other aspects of metabolism was evaluated by MDA composition and catalase activity; NO content, uric acid, Na⁺/K⁺ and Ca⁺²/Mg⁺² activity — ATP-az. Changes in the overall blood count as well as the state of the regulatory components of the immune response by the content of circulating immune complexes and the content of heterogeneous antibodies were evaluated. The data obtained were subjected to standard statistical processing using a coefficient of authenticity. As a result, changes in kidney and liver function, characteristic of the development of hepatorenal syndrome, have been established. According to the results of the study, it is concluded that the systemic metabolism of the animal body changes due to the violation of the properties of cell membranes, slowing the flow of intracellular processes of life, which disrupts the elimination of xenobiotics and plays a negative role in the pathogenesis of hepatorenal insufficiency.
2. Dyrektyva 2010/63 / YeS Yevropeiskoho Parlamentu ta Rady vid 22 veresnia 2010 roku pro zakhyst tvaryn, yaki vykorystovuiutsia v naukovykh tsiliakh [Directive 2010/63 / EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes]. Official Journal of the European Union, 276, 0033–0079. Vziato z http://data.europa.eu/eli/dir/2010/63/oj.
3. Kulitska, M. I. (2015). Funktsionalnyi stan pechinky u shchuriv za umov eksperymentalnoho hepatorenalnoho syndrome [Functional condition of the liver in rats under experimental hepatorenal syndrome]. Medychna ta klinichna khimiia – Medical and clinical chemistry, 65, 74–77. https://doi.org/10.11603/mcch.2410-681X.2015.v17.i4.5726.
4. Kulitska, M. I., Myroniuk, D. B., Krynytska, I. Ya. & Yaremchuk, O. Z. (2015). Patohenetychni aspekty hepatorenalnoho syndromu (ohliad literatury) [Pathogenetic aspects of hepatorenal syndrome (literature review)]. Medychna ta klinichna khimiia – Medical and clinical chemistry, 62, 114–120. Vziato z http://nbuv.gov.ua/UJRN/Medkh_2015_17_1_27.
5. Pro zatverdzhennia Poriadku provedennia naukovymy ustanovamy doslidiv, eksperymentiv na tvarynakh. Nakaz Ministerstva Osvity i Nauky, Molodi ta Sportu Ukrainy № 249 vid 01.03.2012 r. [On approval of the Procedure for conducting scientific experiments, experiments on animals. Order of the Ministry of Education and Science, Youth and Sports of Ukraine No. 249 of 01.03.2012]. Vziato z https://zakon.rada.gov.ua/laws/main/z0416-12.
6. Savchenko, V. M., Nikolenko, Ye. Ya., Sokruto, O. V. & Vovk, K. V. (2009). Hepatorenalnyi syndrom v praktytsi simeinoho likaria (kryterii diahnozu ta likuvannia) [Hepatorenal syndrome in family physician practice (criteria for diagnosis and treatment)]. Visnyk Kharkivskoho natsionalnoho universytetu imeni V. N. Karazina – Bulletin of the VN Karazin Kharkiv National University, 17, 63–72. Vziato z http://dspace.univer.kharkov.ua/handle/ 123456789/4096.
7. Angeli, P., & Merkel, C. (2008). Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. Journal of Hepatology, 48, 93–103.
8. Angeli, P., & Morando, F. (2010). Optimal management of hepatorenal syndrome in patients with cirrhosis. Hepatic Medicine: Evidence and Research, 2, 87–98. https://doi.org/10.2147/HMER.S6918.
9. Dundar, H. Z., & Tuncay, Y. (2015) Management of hepatorenal syndrome. World Journal of Nephrology, 4 (2), 277–286. https://dx.doi.org/10.5527/wjn.v4.i2.277.
10. Licata, A., Maida, M., Bonaccorso, A., & Macaluso, F. S. (2013). Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study. World Journal Hepatol, 5 (12), 685–691. doi:10.4254/wjh.v5.i12.685.
11. Low, G., Alexander, G. J. M., & Lomas, D. J. (2015) Hepatorenal Syndrome: Aetiology, Diagnosis, and Treatment. Gastroenterology Research and Practice. http://dx.doi.org/10.1155/2015/207012.
12. Solà, E., Guevara, M., & Ginès, P. (2013) Current treatment strategies for hepatorenal syndrome.Clinical Liver Disease, 2 (3), 136–139. https://doi.org/10.1002/cld.209.
This work is licensed under a Creative Commons Attribution 4.0 International License.